| Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors G Zhang, DT Frederick, L Wu, Z Wei, C Krepler, S Srinivasan, YC Chae, ... The Journal of clinical investigation 126 (5), 1834-1856, 2016 | 256 | 2016 |
| PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas H Lu, S Liu, G Zhang, B Wu, Y Zhu, DT Frederick, Y Hu, W Zhong, ... Nature 550 (7674), 133-136, 2017 | 160 | 2017 |
| Tumor-associated B-cells induce tumor heterogeneity and therapy resistance R Somasundaram, G Zhang, M Fukunaga-Kalabis, M Perego, C Krepler, ... Nature communications 8 (1), 607, 2017 | 128 | 2017 |
| Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells M Vitiello, A Tuccoli, R D’Aurizio, S Sarti, L Giannecchini, S Lubrano, ... Oncotarget 8 (15), 25395, 2017 | 71 | 2017 |
| Oncogenic BRAF-mediated melanoma cell invasion H Lu, S Liu, G Zhang, LN Kwong, Y Zhu, JP Miller, Y Hu, W Zhong, J Zeng, ... Cell reports 15 (9), 2012-2024, 2016 | 59 | 2016 |
| PERK is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma D Pytel, Y Gao, K Mackiewicz, YV Katlinskaya, KA Staschke, ... PLoS genetics 12 (12), e1006518, 2016 | 51 | 2016 |
| Induction of telomere dysfunction prolongs disease control of therapy-resistant melanoma G Zhang, LW Wu, I Mender, M Barzily-Rokni, MR Hammond, O Ope, ... Clinical Cancer Research 24 (19), 4771-4784, 2018 | 35 | 2018 |
| Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer D Zhang, G Zhang, X Hu, L Wu, Y Feng, S He, Y Zhang, Z Hu, L Yang, ... Cancer research 77 (14), 3745-3757, 2017 | 34 | 2017 |
| Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance J Liu, VW Rebecca, AV Kossenkov, T Connelly, Q Liu, A Gutierrez, M Xiao, ... Cancer research 81 (20), 5230-5241, 2021 | 12 | 2021 |
| Durable clinical response to larotrectinib in an adolescent patient with an undifferentiated sarcoma harboring an STRN-NTRK2 fusion LW Wu, T Pavlock, A Patterson, A Post, C Ambrose, V Rajaram, ... JCO Precision Oncology 2, 2018 | 11 | 2018 |
| Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma LW Wu, G Zhang, M Herlyn Molecular & cellular oncology 3 (4), e1179381, 2016 | 6 | 2016 |
| Pseudohypophosphatemia in a patient with multiple myeloma LW Wu, TS Choi, M Barbosa, H Chong, AGW Wu, KK Soe AACE Clinical Case Reports 6 (6), e334-e337, 2020 | 4 | 2020 |
| Evaluation of the effect of store-and-forward teledermatology on in-person health care system utilization in a safety-net public health and hospital system LW Wu, SK Cho, B Chamseddin, J Ashworth, LS Hynan, BF Chong, ... Journal of the American Academy of Dermatology 85 (4), 1026-1028, 2021 | 2 | 2021 |
| Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas H Lu, S Liu, G Zhang, B Wu, Y Zhu, DT Frederick, Y Hu, W Zhong, ... Nature 565 (7738), E4-E4, 2019 | 2 | 2019 |
| Transformation of metastatic nonfunctioning pancreatic neuroendocrine tumor into insulinoma—two case reports LW Wu, SMQ Hussaini, JW Lee, DH Shu, RH Hruban, DA Laheru Annals of Pancreatic Cancer 5, 2022 | 1 | 2022 |
| Tumor Microenvironment for Melanoma Cells LW Wu, M Herlyn, G Zhang Melanoma Development: Molecular Biology, Genetics and Clinical Application …, 2017 | 1 | 2017 |
| Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition LW Wu, JJ Tao, D McDonnell, B Izar Melanoma Research, 10.1097, 2024 | | 2024 |
| Repurposing an HIV drug to improve efficacy of targeted therapy in melanoma LW Wu, G Zhang, M Herlyn Translational Cancer Research 5 (Suppl 1), 2016 | | 2016 |
